Language:

BRIVA‐LIFE–A multicenter retrospective study of the long‐term use of brivaracetam in clinical practice

Villanueva, Vicente ; López‐González, Francisco Javier ; Mauri, José Angel ; Rodriguez‐Uranga, Juan ; Olivé‐Gadea, Marta ; Montoya, Javier ; Ruiz‐Giménez, Jesus ; Zurita, Jorge ; Abril, J ; Toledo, M ; Garcés, M ; Gómez‐Ibáñez, A ; Hampel, K ; Rodriguez‐Osorio, X ; Poza, JJ ; Campos, D ; Ojeda, J ; Tortosa, D ; Castro‐Vilanova, MD ; Saiz‐Diaz, R ; González de la Aleja, J ; Castillo, A ; de Toledo, M ; Gago‐Veiga, AB ; Piera, A ; Crisostomo, J

Acta neurologica Scandinavica, 2019-04, Vol.139 (4), p.360-368 [Peer Reviewed Journal]

Denmark: Wiley Subscription Services, Inc

Full text available

Citations Cited by

Actions
1. Add to e-Shelf
2. Remove from e-Shelf
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
BRIVA‐LIFE–A multicenter retrospective study of the long‐term use of brivaracetam in clinical practice
Author: Villanueva, Vicente ; López‐González, Francisco Javier ; Mauri, José Angel ; Rodriguez‐Uranga, Juan ; Olivé‐Gadea, Marta ; Montoya, Javier ; Ruiz‐Giménez, Jesus ; Zurita, Jorge ; Abril, J ; Toledo, M ; Garcés, M ; Gómez‐Ibáñez, A ; Hampel, K ; Rodriguez‐Osorio, X ; Poza, JJ ; Campos, D ; Ojeda, J ; Tortosa, D ; Castro‐Vilanova, MD ; Saiz‐Diaz, R ; González de la Aleja, J ; Castillo, A ; de Toledo, M ; Gago‐Veiga, AB ; Piera, A ; Crisostomo, J
Subjects: Adolescent ; Adult ; Aged ; Anticonvulsants - therapeutic use ; Antiepileptic agents ; Clinical medicine ; Convulsions & seizures ; Dosage ; Drug Resistant Epilepsy - drug therapy ; Epilepsies, Partial - drug therapy ; Epilepsy ; Etiracetam ; Female ; Humans ; Male ; Medical records ; Middle Aged ; Patients ; Pyrrolidinones - therapeutic use ; Retrospective Studies ; Seizures ; Seizures - prevention & control ; Treatment Outcome ; Young Adult
Is Part Of: Acta neurologica Scandinavica, 2019-04, Vol.139 (4), p.360-368
Notes: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Description: Objectives Evaluate long‐term effectiveness and tolerability of brivaracetam in clinical practice in patients with focal epilepsy. Materials and Methods This was a multicenter retrospective study. Patients aged ≥16 years were started on brivaracetam from November 2016 to June 2017 and followed over 1 year. Data were obtained from medical records at 3, 6 and 12 months after treatment initiation for evaluation of safety‐ and seizure‐related outcomes. Results A total of 575 patients were included in analyses; most had been treated with ≥4 lifetime antiepileptic drugs. Target dosage was achieved by 30.6% of patients on the first day. Analysis of primary variables at 12 months revealed that mean reduction in seizure frequency was 36.0%, 39.7% of patients were ≥50% responders and 17.5% were seizure‐free. Seizure‐freedom was achieved by 37.5% of patients aged ≥65 years. Incidence of adverse events (AEs) and psychiatric AEs (PAEs) was 39.8% and 14.3%, respectively, and discontinuation due to these was 8.9% and 3.7%, respectively. Somnolence, irritability, and dizziness were the most frequently reported AEs. At baseline, 228 (39.7%) patients were being treated with levetiracetam; most switched to brivaracetam (dose ratio 1:10‐15). Among those who switched because of PAEs (n = 53), 9 (17%) reported PAEs on brivaracetam, and 3 (5.7%) discontinued because of PAEs. Tolerability was not highly affected among patients with learning disability or psychiatric comorbidity. Conclusions In a large population of patients with predominantly drug‐resistant epilepsy, brivaracetam was effective and well‐tolerated; no unexpected AEs occurred over 1 year, and the incidence of PAEs was lower compared with levetiracetam.
Publisher: Denmark: Wiley Subscription Services, Inc
Language: English

Links

View this record in MEDLINE/PubMed

Back to results list

Previous Result 5 Next Go to Next page

Implemented by: Social Network Logos:

BRIVA‐LIFE–A multicenter retrospective study of the long‐term use of brivaracetam in clinical practice

Denmark: Wiley Subscription Services, Inc

Searching Remote Databases, Please Wait